JUDGED BY PROFESSIONALS FROM

 

THE PROMPT

The Covid-19 epidemic has shown the lack of ‘corporate immunity’ of the pharmaceutical industry to systemic risk. Most companies globalized their business models to access new markets and reduce production costs, but doing so inevitably increased the fragmentation of their value chains across geographies – thereby amplifying firms’ exposure to global shocks and their supply-chain dependence on Asian countries. This situation has significantly raised the risk of drug shortages in western markets during the Covid-19 outbreak. This intriguing strategic dilemma has been exacerbated by the fact that European governments have recently urged pharmaceutical companies to repatriate production to help reestablish national sovereignty.

Select a pharmaceutical company and propose whether it should change its supply chain strategy over the next 5 years given the business challenges highlighted, and politics changed, by the Covid-19 crisis. If not, why? If so, why and what changes would you recommend?

 

PARTICIPATING UNIVERSITIES

Beyond Disruption is a case competition across top European business school programs including Oxford's Saïd Business School, HEC Paris, London  Business School, INSEAD, and Cambridge's Judge Business School

cargo-dark.jpg

THE JUDGES

Bernard_Naughton_square.jpg
BERNARD NAUGHTON, PHD

Medical supply chain specialist and Pharmacist,

University of Oxford

PatrickJudge.jpg
PATRICK GAPARAYI, BPharm, MSc

Supply Chain Manager,

UNICEF

VICTORIA GOOD, MChem

Project Leader specialising in Operations and Healthcare

BCG

tonycook.jpg
TONY COOK
BSc

Director of Global Supply Chain Planning (Oncology) GSK

KEYNOTE

ELENA TRAJKOVSKA

Chief Logistics, Warehouse and Inventory Management Center,

UNICEF

 

ASK US A QUESTION

Please also feel free to contact us about finding teammates at your university and we will do our best to connect you